Therapeutic Asset Ratings
220 results matching 1 filter
133,990 assets · 8,802 sponsors · 3,128 indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
Atezolizumab
Gastric Cancer
Genentech, Inc.
P2
B
(56)
Durvalumab
Gastric Cancer
Second Affiliated Hospital of Guangzhou Medical University
P2
B
(56)
(+)-VINCRISTINE
Gastric Cancer
BeOne Medicines
P2
B
(56)
TIL
Gastric Cancer
Intima Bioscience, Inc.
P2
CCC
(55)
Ipilimumab
Gastric Cancer
Neonc Technologies, Inc.
P2
CCC
(54)
Datopotamab Deruxtecan
Gastric Cancer
AstraZeneca
P2
CCC
(52)
FLUDEOXYGLUCOSE
Gastric Cancer
National Cancer Institute (NCI)
P2
CCC
(52)
Givastomig
Gastric Cancer
I-Mab Biopharma US Limited
P2
CCC
(52)
Letrozole
Gastric Cancer
Blueprint Medicines Corporation
P2
CCC
(52)
Levoleucovorin
Gastric Cancer
Shenzhen Xinhe Biomedical
P2
CCC
(52)
Olaparib
Gastric Cancer
Qilu Pharmaceutical Co., Ltd.
P2
CCC
(52)
Pemigatinib
Gastric Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
P2
CCC
(52)
Rilvegostomig
Gastric Cancer
AstraZeneca
P2
CCC
(52)
S-1
Gastric Cancer
Genentech, Inc.
P2
CCC
(52)
Surufatinib
Gastric Cancer
RenJi Hospital
P2
CCC
(52)
FAPI74
Gastric Cancer
National Cancer Institute (NCI)
P2
CCC
(51)
LENVATINIB
Gastric Cancer
Peking University
P2
CCC
(51)
Terelizumab
Gastric Cancer
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
P2
CCC
(51)
Cediranib
Gastric Cancer
National Cancer Institute (NCI)
P1
CCC
(51)
Avelumab
Gastric Cancer
Ocellaris Pharma, Inc.
P2
CCC
(48)
azd0901
Gastric Cancer
AstraZeneca
P2
CCC
(48)
CHLOROPTIC-P S.O.P. COMPONENT PREDNISOLONE
Gastric Cancer
AstraZeneca
P2
CCC
(48)
Cytosin-Arabinosid
Gastric Cancer
RenJi Hospital
P2
CCC
(48)
Daunorubicin
Gastric Cancer
RenJi Hospital
P2
CCC
(48)
ep0057
Gastric Cancer
Ellipses Pharma
P2
CCC
(48)
Showing 26 to 50 of 220 assets
Previous
Page 2 of 9
Next
